TranScrip Partners appoints David Oxlade as Chairman of the Board
David Oxlade is a former CEO of Xenova, the LSE and NASDAQ listed biotechnology company, and in 2006 was appointed Chairman of BioAnaLab, the analytical service organisation acquired in 2009 by Millipore Corporation. Prior to their acquisition by Roche, David spent 14 years working for Boehringer Mannheim and a further seven serving as President of Californian-based, Syva (a subsidiary of Hoechst AG),.
David is an Honorary Fellow of Brunel University, has held membership of the Emerging Enterprise Council of EuropaBio and the Bioscience Leadership Council since its inception. He has chaired the European Working Group of the Bioscience Innovation and Growth Team, set up by the UK Government under Sir David Cooksey to establish a ten year agenda for its bioscience industry.
Most read news
Other news from the department people
These products might interest you
Genomics & Analytical Services by Azenta
Integrated Genomics & Analytical Services from Azenta Life Sciences
Discovery can be challenging work. Until you find the right genomics partner.
Pharmaceutical Development Services by AR2i
Take Advantage of AR2i's Analytical Knowledge and Unique Expertise
Our Pharmaceutical Laboratory Services According to the European Pharmacopoeia or Client Needs
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.